| Literature DB >> 35051169 |
Mary-Ann El Sharouni1, Paul J van Diest2, Willeke A M Blokx2.
Abstract
INTRODUCTION: Because of different therapeutic regimens for superficial and non-superficial basal cell carcinomas (BCCs), accurate histopathological examination of a punch biopsy to determine its subtype is essential. The aim of the current study was to evaluate the additional yield of a more extensive step-section method to that of a standard histologic examination at 4 levels.Entities:
Mesh:
Year: 2022 PMID: 35051169 PMCID: PMC8775292 DOI: 10.1371/journal.pone.0256149
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinicopathological characteristics of all included patients.
| Total, n = 100 | |
|---|---|
|
| |
| Female | 45 (45.0) |
| Male | 55 (55.0) |
|
| 59 (28–85) |
|
| |
| Head and neck | 11 (11.0) |
| Trunk | 51 (51.0) |
| Arms | 7 (7.0) |
| Legs | 31 (31.0) |
|
| |
| No | 11 (11.0) |
| Yes | 89 (89.0) |
|
| 0.8 (0.2–4.0) |
|
| |
| 2mm | 30 (30.0) |
| 3mm | 65 (65.0) |
| 4mm | 4 (4.0) |
| 5mm | 1 (1.0) |
|
| 0.3 (0.2–1.1) |
* Available for 56 patients.
Fig 1Examples of the HE sections of the standard histologic examination at 4 levels (HE 1–4, upper panel from left to right) and the HE sections of the 4 additional levels (HE 5–8, lower panel from left to right). In this example, an additional nodular component was found in level 6, 7 and 8.
Clinicopathological characteristics of patients with a more aggressive subtype in additional step sections (levels 5–8) vs. the remaining patients.
| More aggressive subtype in levels 5–8 N = 14 | No aggressive subtype in levels 5–8 N = 86 | p-value | |
|---|---|---|---|
|
| 0.18 | ||
| Female | 4 (28.6) | 41 (47.7) | |
| Male | 10 (71.4) | 45 (52.3) | |
|
| 67 (41–85) | 58 (28–83) | 0.30 |
|
| 0.02 | ||
| Head and neck | 5 (35.7) | 6 (7.0) | |
| Trunk | 5 (35.7) | 46 (53.6) | |
| Arms | 1 (7.1) | 6 (7.0) | |
| Legs | 3 (21.4) | 28 (32.6) | |
|
| 1.1 (0.3–2.1) | 0.8 (0.2–4.0) | 0.40 |
|
| 0.90 | ||
| 2mm | 26 (30.2) | 4 (28.6) | |
| 3mm | 56 (65.1) | 9 (64.3) | |
| 4mm | 3 (3.5) | 1 (7.1) | |
| 5mm | 1 (1.2) | (0.0) | |
|
| 0.6 (0.5–1.1) | 0.3 (0.2–0.4) | <0.0001 |
* Available in 11 patients.
** Available in 45 patients.
Overview of HE levels of the 14 patients with a more aggressive BCC component in deeper HE slides (levels 5–8).
All patients had a deeper, nodular component. sBCC = superficial basal cell carcinoma, nBCC = nodular basal cell carcinoma.
| Patient nr | Level | |||||||
|---|---|---|---|---|---|---|---|---|
| Standard sectioning level | Additional, deeper sectioning levels | |||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | NA |
|
| sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC | NA |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | sBCC | sBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | sBCC | sBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
|
| sBCC | sBCC | sBCC | sBCC | nBCC | sBCC | sBCC | sBCC |
|
| sBCC | sBCC | sBCC | sBCC | sBCC | nBCC | nBCC | nBCC |
NA = No tissue left for this additional sectioning.